AKYNZEO

Peak

netupitant and palonosetron

Helsinn
NDAORALCAPSULE
Approved
Oct 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1

Mechanism of Action

Neurokinin 1 Antagonists

Pharmacologic Class:

Substance P/Neurokinin-1 Receptor Antagonist

Indications (8)

combination with dexamethasone in adults for the prevention of acutedelayed nauseavomiting associated with initialrepeat courses of highly emetogenic cancer chemotherapyrepeat courses of cancer chemotherapyincludingbut not limited tohighly emetogenic chemotherapy

Clinical Trials (1)

NCT03097588Phase 2Completed

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

Started Apr 2017
43 enrolled
Malignant Neoplasm

Loss of Exclusivity

LOE Date
Sep 25, 2035
116 months away
Patent Expiry
Sep 25, 2035

Patent Records (5)

Patent #ExpiryTypeUse Code
8951969
Nov 18, 2030
Product
—
8623826
Nov 18, 2030
U-2293
9186357
Nov 18, 2030
U-2293
9943515
Nov 18, 2030
U-2293
11559523
Nov 18, 2030
Product
U-3522
Company
Helsinn
Helsinn
Ireland - Dublin
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers